About this trial
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastography (MREL), as non-invasive biomarkers to assess two primary pathophysiological processes of AILD: bile duct damage and liver fibrosis. In this cross-sectional study MRI based findings of bile duct injury and liver fibrosis will be correlated with both liver histology and circulating biomarkers of these disease processes.
Eligibility criteria
Qualifiers
Age 6-23 years old.
Established or suspected clinical diagnosis of AIH or PSC.
Disqualifiers
History of liver transplantation.
Chronic Hepatitis B or untreated hepatitis C virus infection.
Pregnancy.
Absolute contraindication for MRI (e.g. pacemaker, metallic implants, claustrophobia).
Trial design
Treatments tested in this trial
- Not listed